Stephanie A Mullane1, Eliezer M Van Allen. 1. aDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston bCancer Program, Broad Institute of MIT and Harvard, Cambridge cCenter for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Precision cancer medicine, the use of genomic profiling of patient tumors at the point-of-care to inform treatment decisions, is rapidly changing treatment strategies across cancer types. Precision medicine for advanced prostate cancer may identify new treatment strategies and change clinical practice. In this review, we discuss the potential and challenges of precision medicine in advanced prostate cancer. RECENT FINDINGS: Although primary prostate cancers do not harbor highly recurrent targetable genomic alterations, recent reports on the genomics of metastatic castration-resistant prostate cancer has shown multiple targetable alterations in castration-resistant prostate cancer metastatic biopsies. Therapeutic implications include targeting prevalent DNA repair pathway alterations with PARP-1 inhibition in genomically defined subsets of patients, among other genomically stratified targets. In addition, multiple recent efforts have demonstrated the promise of liquid tumor profiling (e.g., profiling circulating tumor cells or cell-free tumor DNA) and highlighted the necessary steps to scale these approaches in prostate cancer. SUMMARY: Although still in the initial phase of precision medicine for prostate cancer, there is extraordinary potential for clinical impact. Efforts to overcome current scientific and clinical barriers will enable widespread use of precision medicine approaches for advanced prostate cancer patients.
PURPOSE OF REVIEW: Precision cancer medicine, the use of genomic profiling of patienttumors at the point-of-care to inform treatment decisions, is rapidly changing treatment strategies across cancer types. Precision medicine for advanced prostate cancer may identify new treatment strategies and change clinical practice. In this review, we discuss the potential and challenges of precision medicine in advanced prostate cancer. RECENT FINDINGS: Although primary prostate cancers do not harbor highly recurrent targetable genomic alterations, recent reports on the genomics of metastatic castration-resistant prostate cancer has shown multiple targetable alterations in castration-resistant prostate cancer metastatic biopsies. Therapeutic implications include targeting prevalent DNA repair pathway alterations with PARP-1 inhibition in genomically defined subsets of patients, among other genomically stratified targets. In addition, multiple recent efforts have demonstrated the promise of liquid tumor profiling (e.g., profiling circulating tumor cells or cell-free tumor DNA) and highlighted the necessary steps to scale these approaches in prostate cancer. SUMMARY: Although still in the initial phase of precision medicine for prostate cancer, there is extraordinary potential for clinical impact. Efforts to overcome current scientific and clinical barriers will enable widespread use of precision medicine approaches for advanced prostate cancerpatients.
Authors: S F Slovin; C S Higano; O Hamid; S Tejwani; A Harzstark; J J Alumkal; H I Scher; K Chin; P Gagnier; M B McHenry; T M Beer Journal: Ann Oncol Date: 2013-03-27 Impact factor: 32.976
Authors: Ilir Agalliu; Erika M Kwon; Daniel Zadory; Laura McIntosh; Joseph Thompson; Janet L Stanford; Elaine A Ostrander Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway Journal: Nature Date: 2011-02-10 Impact factor: 49.962
Authors: Jens G Lohr; Viktor A Adalsteinsson; Kristian Cibulskis; Atish D Choudhury; Mara Rosenberg; Peter Cruz-Gordillo; Joshua M Francis; Cheng-Zhong Zhang; Alex K Shalek; Rahul Satija; John J Trombetta; Diana Lu; Naren Tallapragada; Narmin Tahirova; Sora Kim; Brendan Blumenstiel; Carrie Sougnez; Alarice Lowe; Bang Wong; Daniel Auclair; Eliezer M Van Allen; Mari Nakabayashi; Rosina T Lis; Gwo-Shu M Lee; Tiantian Li; Matthew S Chabot; Amy Ly; Mary-Ellen Taplin; Thomas E Clancy; Massimo Loda; Aviv Regev; Matthew Meyerson; William C Hahn; Philip W Kantoff; Todd R Golub; Gad Getz; Jesse S Boehm; J Christopher Love Journal: Nat Biotechnol Date: 2014-04-20 Impact factor: 54.908
Authors: Yuan Yuan; Eliezer M Van Allen; Larsson Omberg; Nikhil Wagle; Ali Amin-Mansour; Artem Sokolov; Lauren A Byers; Yanxun Xu; Kenneth R Hess; Lixia Diao; Leng Han; Xuelin Huang; Michael S Lawrence; John N Weinstein; Josh M Stuart; Gordon B Mills; Levi A Garraway; Adam A Margolin; Gad Getz; Han Liang Journal: Nat Biotechnol Date: 2014-06-22 Impact factor: 54.908
Authors: David T Miyamoto; Yu Zheng; Ben S Wittner; Richard J Lee; Huili Zhu; Katherine T Broderick; Rushil Desai; Douglas B Fox; Brian W Brannigan; Julie Trautwein; Kshitij S Arora; Niyati Desai; Douglas M Dahl; Lecia V Sequist; Matthew R Smith; Ravi Kapur; Chin-Lee Wu; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber Journal: Science Date: 2015-09-18 Impact factor: 47.728
Authors: P N Lara; M Plets; C Tangen; E Gertz; N J Vogelzang; M Hussain; P W Twardowski; M G Garzotto; J P Monk; M Carducci; A Goldkorn; P C Mack; I Thompson; M Van Loan; D I Quinn Journal: Cancer Treat Res Commun Date: 2018-04-28
Authors: Rafael E Jimenez; Thomas D Atwell; Hughes Sicotte; Bruce Eckloff; Liguo Wang; Poulami Barman; Jason P Sinnwell; Patrick W Eiken; Brendan P McMenomy; Winston Tan; Liewei Wang; Rachel E Carlson; Manish Kohli Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2019-02-26
Authors: Lisanne F van Dessel; Job van Riet; Minke Smits; Yanyun Zhu; Paul Hamberg; Michiel S van der Heijden; Andries M Bergman; Inge M van Oort; Ronald de Wit; Emile E Voest; Neeltje Steeghs; Takafumi N Yamaguchi; Julie Livingstone; Paul C Boutros; John W M Martens; Stefan Sleijfer; Edwin Cuppen; Wilbert Zwart; Harmen J G van de Werken; Niven Mehra; Martijn P Lolkema Journal: Nat Commun Date: 2019-11-20 Impact factor: 14.919